In contrast, results from a phase I trial involving patients with metastatic HER2-overexpressing breast cancer indicated that patients generally tolerated the combination of Everolimus with trastuzumab and paclitaxel well, showing encouraging antitumor activity. This evidence concerns the gene ERBB2 and breast cancer.